Comparing SG&A Expenses: Amgen Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Amgen Inc., a titan in the field, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amgen's SG&A expenses grew by approximately 31%, peaking at $6.18 billion in 2023. This reflects a strategic investment in marketing and administrative capabilities to maintain its market dominance.

Conversely, Rhythm Pharmaceuticals, Inc., a smaller player, has shown a dramatic increase in SG&A expenses, skyrocketing from a modest $1.21 million in 2014 to $117.53 million in 2023. This represents an exponential growth of over 9,600%, highlighting Rhythm's aggressive expansion and market penetration efforts.

These contrasting trends underscore the diverse strategies employed by biotech companies to navigate the complexities of the industry, offering valuable insights into their operational priorities.